{"transactions":[{"id":1085928,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Operations"}}],"security":"Common Stock, $0.01 Par Value","published_at":"2025-07-18T00:45:55.000Z","date":"2025-07-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":11896,"price":3.85,"value":45799.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,888 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":349841,"source":{"system":"sec-edgar","filing":"0000950170-25-096736","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017025096736/ownership.xml","form_type":"4"}},{"id":1189199,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Operations"}}],"security":"Common Stock, $.01 Par Value","published_at":"2025-03-29T00:20:54.000Z","date":"2025-03-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":16407,"price":5.1,"value":83675.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units."}],"balance_after":357849,"source":{"system":"sec-edgar","filing":"0000950170-25-047092","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017025047092/ownership.xml","form_type":"4"}},{"id":1453123,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Operating Officer"}}],"security":"Common Stock, $0.01 Par Value","published_at":"2024-07-17T23:50:18.000Z","date":"2024-07-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1817,"price":5.83,"value":10593.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units."}],"balance_after":374256,"source":{"system":"sec-edgar","filing":"0000950170-24-084407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017024084407/ownership.xml","form_type":"4"}},{"id":1453122,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Operating Officer"}}],"security":"Common Stock, $0.01 Par Value","published_at":"2024-07-17T23:50:18.000Z","date":"2024-06-30","kind":"grant","planned":false,"acquired":true,"shares":722,"price":3.09,"value":2230.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired through the Issuer's Employee Stock Purchase Plan."}],"balance_after":376073,"source":{"system":"sec-edgar","filing":"0000950170-24-084407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017024084407/ownership.xml","form_type":"4"}},{"id":1512527,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Operating Officer"}}],"security":"Performance Restricted Stock Unit","published_at":"2024-05-18T01:00:15.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":158000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The performance-based restricted stock unit will vest on July 15, 2027.  The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The performance-based restricted stock unit will vest on July 15, 2027.  The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above."}],"balance_after":158000,"derivative":{"underlying":"Common Stock, $.01 Par Value","underlying_shares":158000},"source":{"system":"sec-edgar","filing":"0000950170-24-062065","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017024062065/ownership.xml","form_type":"4"}},{"id":1512526,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Operating Officer"}}],"security":"Common Stock, $.01 Par Value","published_at":"2024-05-18T01:00:15.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":129000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested."}],"balance_after":375351,"source":{"system":"sec-edgar","filing":"0000950170-24-062065","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017024062065/ownership.xml","form_type":"4"}},{"id":1557892,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Operating Officer"}}],"security":"Common Stock, $.01 Par Value","published_at":"2024-03-30T01:00:06.000Z","date":"2024-03-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":17084,"price":4.63,"value":79098.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units."}],"balance_after":246351,"source":{"system":"sec-edgar","filing":"0000950170-24-038816","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017024038816/ownership.xml","form_type":"4"}},{"id":1659774,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Operating Officer"}}],"security":"Common Stock, $0.01 Par Value","published_at":"2024-02-05T11:00:15.000Z","date":"2024-02-04","kind":"grant","planned":false,"acquired":true,"shares":15290,"price":3.27,"value":49998.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024."}],"balance_after":263435,"source":{"system":"sec-edgar","filing":"0001209191-24-002740","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899460/000120919124002740/doc4.xml","form_type":"4"}},{"id":1659773,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Operating Officer"}}],"security":"Common Stock, $0.01 Par Value","published_at":"2024-02-05T11:00:15.000Z","date":"2023-12-31","kind":"grant","planned":false,"acquired":true,"shares":711,"price":3.09,"value":2196.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Includes 711 shares of common stock purchased under the Company's Employee Stock Purchase Plan on December 31, 2023 in an exempt transaction."}],"balance_after":248145,"source":{"system":"sec-edgar","filing":"0001209191-24-002740","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000120919124002740/doc4.xml","form_type":"4"}},{"id":1877209,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Operating Officer"}}],"security":"Performance Restricted Stock Unit","published_at":"2023-05-27T01:00:54.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023.  The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows:  less than 25th percentile=0% of target,  25th percentile=50% of target,  50th percentile=100% of target,  75th percentile=200% percent of target,  90th percentile or higher=300% maximum.  Payout values will be interpolated between the percentile rankings above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023.  The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows:  less than 25th percentile=0% of target,  25th percentile=50% of target,  50th percentile=100% of target,  75th percentile=200% percent of target,  90th percentile or higher=300% maximum.  Payout values will be interpolated between the percentile rankings above."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023.  The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows:  less than 25th percentile=0% of target,  25th percentile=50% of target,  50th percentile=100% of target,  75th percentile=200% percent of target,  90th percentile or higher=300% maximum.  Payout values will be interpolated between the percentile rankings above."}],"balance_after":28000,"derivative":{"underlying":"Common Stock, $.01 Par Value","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001209191-23-032730","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899460/000120919123032730/doc4.xml","form_type":"4"}},{"id":1877208,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Operating Officer"}}],"security":"Common Stock, $.01 Par Value","published_at":"2023-05-27T01:00:54.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":23250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"Acquired pursuant to a Restricted Stock Unit Award:  25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested."}],"balance_after":247434,"source":{"system":"sec-edgar","filing":"0001209191-23-032730","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000120919123032730/doc4.xml","form_type":"4"}},{"id":1880327,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Operating Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-05-25T01:00:13.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"4-year vesting schedule with 1/4th of shares vesting on the first anniversary of the vesting determination date and on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date.  The vesting determination date for this grant is March 27, 2023."}],"balance_after":224184,"source":{"system":"sec-edgar","filing":"0001209191-23-032031","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000120919123032031/doc4.xml","form_type":"4"}},{"id":1894151,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Operating Officer"}}],"security":"Common Stock,$.01 par value","published_at":"2023-05-15T21:01:00.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":14184,"price":4.23,"value":59998.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on May 13, 2023."}],"balance_after":14184,"source":{"system":"sec-edgar","filing":"0001209191-23-029518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000120919123029518/doc4.xml","form_type":"4"}},{"id":2164535,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-09-07T08:00:39.000Z","date":"2022-09-03","kind":"tax_withholding","acquired":false,"shares":1511,"price":0.398,"value":601.378,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuers Common Stock that were withheld to cover tax liability in connection with vesting and settlement of restricted stock units reported on a prior Form 4."}],"balance_after":10710,"source":{"system":"sec-edgar","filing":"0001209191-22-048948","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919122048948/doc4.xml","form_type":"4"}},{"id":2576454,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-08T07:21:30.000Z","date":"2021-09-03","kind":"tax_withholding","acquired":false,"shares":1511,"price":4.38,"value":6618.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with vesting and settlement of restricted stock units reported on a prior Form 4."}],"balance_after":12221,"source":{"system":"sec-edgar","filing":"0001209191-21-055101","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919121055101/doc4.xml","form_type":"4"}},{"id":2807104,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-05T18:36:02.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":11125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of restricted stock units, each representing a contingent right to one share of common stock which, subject to continued service, vests in installments of 40%, 20%, and 40% at 6 months, 12 months, and 18 months, respectively, after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Holdings were adjusted to reflect the issuer's 1-for-6 reverse stock split effected on December 31, 2020."}],"balance_after":13732,"source":{"system":"sec-edgar","filing":"0001209191-21-018360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919121018360/doc4.xml","form_type":"4"}},{"id":3026330,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-09-21T08:35:26.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":3015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded."}],"balance_after":15639,"source":{"system":"sec-edgar","filing":"0001209191-20-051241","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919120051241/doc4.xml","form_type":"4"}},{"id":3353134,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-12-04T07:51:37.000Z","date":"2019-12-02","kind":"sale","acquired":false,"shares":1513,"price":1.6002,"value":2421.1026,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $1.53 to $1.68 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":12624,"source":{"system":"sec-edgar","filing":"0001209191-19-058938","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119058938/doc4.xml","form_type":"4"}},{"id":3375448,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-11-12T08:15:09.000Z","date":"2019-11-07","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options issued under the issuer's 2015 Omnibus Incentive Compensation Plan.  The shares subject to the options vest in equal quarterly installments over two years beginning on November 7, 2019 with the first quarterly installment vesting on February 7, 2020."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2029-11-07","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-19-055907","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119055907/doc4.xml","form_type":"4"}},{"id":3600152,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-12T16:23:35.000Z","date":"2019-03-08","kind":"grant","acquired":true,"shares":15075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2019 with the first quarterly installment vesting on April 1, 2019."}],"balance_after":15075,"derivative":{"exercise_price":13.51,"expiration_date":"2029-03-08","underlying":"Common Stock","underlying_shares":15075},"source":{"system":"sec-edgar","filing":"0001209191-19-018797","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119018797/doc4.xml","form_type":"4"}},{"id":3600151,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-12T16:23:35.000Z","date":"2019-03-08","kind":"grant","acquired":true,"shares":9045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2019, December 1, 2020, December 1, 2021 and December 1, 2022."}],"balance_after":14137,"source":{"system":"sec-edgar","filing":"0001209191-19-018797","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119018797/doc4.xml","form_type":"4"}},{"id":3636717,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-02-25T16:19:04.000Z","date":"2019-02-22","kind":"sale","acquired":false,"shares":761,"price":13.1777,"value":10028.2297,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that were sold to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $12.9615 to $13.1800 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":5092,"source":{"system":"sec-edgar","filing":"0001209191-19-012975","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119012975/doc4.xml","form_type":"4"}},{"id":3718377,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-12-27T08:14:55.000Z","date":"2018-12-22","kind":"grant","acquired":true,"shares":2200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded."}],"balance_after":5853,"source":{"system":"sec-edgar","filing":"0001209191-18-064143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118064143/doc4.xml","form_type":"4"}},{"id":3722403,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-12-21T17:17:35.000Z","date":"2018-06-28","kind":"sale","acquired":false,"shares":3774,"price":27.84,"value":105068.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 2, 2018, the reporting person filed a Form 4 reporting the June 28, 2018 sale of 5,859 shares of common stock pursuant to a Rule 10b5-1 plan. The report person's broker subsequently acknowledged that of the 5,859 shares, 2,085 were erroneously sold by the broker. The sale of the 2,085 shares was unwound through the broker's error account and therefore did not occur for purposes of the reporting person's account. This Form 4 amends and restates, in its entirety, the transaction reported in the July 2, 2018 Form 4 in order to correctly report the disposition of 3,774 shares of the issuer's common stock pursuant to the reporting person's Rule 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $27.45 to $28.15 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On July 2, 2018, the reporting person filed a Form 4 reporting the June 28, 2018 sale of 5,859 shares of common stock pursuant to a Rule 10b5-1 plan. The report person's broker subsequently acknowledged that of the 5,859 shares, 2,085 were erroneously sold by the broker. The sale of the 2,085 shares was unwound through the broker's error account and therefore did not occur for purposes of the reporting person's account. This Form 4 amends and restates, in its entirety, the transaction reported in the July 2, 2018 Form 4 in order to correctly report the disposition of 3,774 shares of the issuer's common stock pursuant to the reporting person's Rule 10b5-1 plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"As a result of the overstatement of the number of shares sold on the reporting person's July 2, 2018 Form 4, the reporting person's subsequently filed Form 4s have understated her ownership of the issuer's common stock by 2,085 shares. As of the date of this amendment, the reporting person directly holds 3,653 shares of the issuer's common stock."}],"balance_after":7391,"source":{"system":"sec-edgar","filing":"0001209191-18-063965","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118063965/doc4a.xml","form_type":"4/A","original_submission_date":"2018-07-02"}},{"id":3742190,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-12-06T08:31:35.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":4119,"price":20.6557,"value":85080.8283,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Sales pursuant to a 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.2500 to $20.7900 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1568,"source":{"system":"sec-edgar","filing":"0001209191-18-061113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118061113/doc4.xml","form_type":"4"}},{"id":3742189,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-12-06T08:31:35.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":1072,"price":20.2012,"value":21655.6864,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.0600 to $20.2500 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":5687,"source":{"system":"sec-edgar","filing":"0001209191-18-061113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118061113/doc4.xml","form_type":"4"}},{"id":3771805,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-11-07T16:11:33.000Z","date":"2018-11-05","kind":"tax_withholding","acquired":false,"shares":747,"price":20.28,"value":15149.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4."}],"balance_after":6759,"source":{"system":"sec-edgar","filing":"0001209191-18-057559","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118057559/doc4.xml","form_type":"4"}},{"id":3818773,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-09-12T16:19:03.000Z","date":"2018-09-10","kind":"grant","acquired":true,"shares":2200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded."}],"balance_after":7506,"source":{"system":"sec-edgar","filing":"0001209191-18-050637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118050637/doc4.xml","form_type":"4"}},{"id":3879313,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-07-02T07:52:32.000Z","date":"2018-06-28","kind":"sale","acquired":false,"shares":5859,"price":27.8443,"value":163139.7537,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $27.45 to $28.15 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":5306,"source":{"system":"sec-edgar","filing":"0001209191-18-040132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118040132/doc4.xml","form_type":"4"}},{"id":3897389,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-06-12T07:40:15.000Z","date":"2018-06-08","kind":"exercise","acquired":false,"shares":24375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sale pursuant to a 10b5-1 plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest over two years from the May 1, 2017 grant date, with the first 25% having vested at the end of six months\nafter the grant date and the remaining 75% vesting in equal quarterly installments over the remainder of such two year period."}],"balance_after":40625,"derivative":{"exercise_price":16.5,"expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":24375},"source":{"system":"sec-edgar","filing":"0001209191-18-037138","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118037138/doc4.xml","form_type":"4"}},{"id":3897388,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-06-12T07:40:15.000Z","date":"2018-06-08","kind":"sale","acquired":false,"shares":24375,"price":35,"value":853125.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sale pursuant to a 10b5-1 plan."}],"balance_after":11165,"source":{"system":"sec-edgar","filing":"0001209191-18-037138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118037138/doc4.xml","form_type":"4"}},{"id":3897387,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-06-12T07:40:15.000Z","date":"2018-06-08","kind":"exercise","acquired":true,"shares":24375,"price":16.5,"value":402187.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise and sale pursuant to a 10b5-1 plan."}],"balance_after":35540,"source":{"system":"sec-edgar","filing":"0001209191-18-037138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118037138/doc4.xml","form_type":"4"}},{"id":3922720,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-05-22T16:35:12.000Z","date":"2018-05-18","kind":"sale","acquired":false,"shares":7288,"price":23.665,"value":172470.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $23.45 to $24.15 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":11165,"source":{"system":"sec-edgar","filing":"0001209191-18-032315","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118032315/doc4.xml","form_type":"4"}},{"id":4001624,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-12T08:36:44.000Z","date":"2018-03-08","kind":"tax_withholding","acquired":false,"shares":2085,"price":25.65,"value":53480.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4."}],"balance_after":18453,"source":{"system":"sec-edgar","filing":"0001209191-18-018701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118018701/doc4.xml","form_type":"4"}},{"id":4034877,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-02-26T08:37:41.000Z","date":"2018-02-22","kind":"grant","acquired":true,"shares":5859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded."}],"balance_after":20538,"source":{"system":"sec-edgar","filing":"0001209191-18-013211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118013211/doc4.xml","form_type":"4"}},{"id":4143002,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-12-05T07:44:44.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":1670,"price":20.5323,"value":34288.941,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.20 to $20.85 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":14679,"source":{"system":"sec-edgar","filing":"0001209191-17-063698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117063698/doc4.xml","form_type":"4"}},{"id":4335915,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-05-03T16:20:55.000Z","date":"2017-05-01","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest over two years from the May 1, 2017 grant date, with the first 25% to vest at the end of six months after the grant date and the remaining 75% to vest in equal quarterly installments over the remainder of such two year period."}],"balance_after":65000,"derivative":{"exercise_price":16.5,"expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-17-029656","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117029656/doc4.xml","form_type":"4"}},{"id":4405881,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-03-03T16:36:58.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2017 with the first quarterly installment vesting on April 1, 2017."}],"balance_after":11000,"derivative":{"exercise_price":27.475,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-17-017615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117017615/doc4.xml","form_type":"4"}},{"id":4405880,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-03-03T16:36:58.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":4400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2017, December 1, 2018, December 1, 2019 and December 1, 2020."}],"balance_after":16349,"source":{"system":"sec-edgar","filing":"0001209191-17-017615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919117017615/doc4.xml","form_type":"4"}},{"id":4533947,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":77439,"kind":"person","name":"Sabella Lauren M","position":1,"cik":"0001360928","reported_name":"Sabella Lauren M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2016-12-05T17:14:14.000Z","date":"2016-12-01","kind":"sale","acquired":false,"shares":2429,"price":20.7415,"value":50381.1035,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sales pursuant to a 10b5-1 plan.  These sales are primarily intended to cover the tax liability resulting from restricted stock vesting."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.30 to $21.15 per share.  The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":11949,"source":{"system":"sec-edgar","filing":"0001209191-16-153410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919116153410/doc4.xml","form_type":"4"}}]}